IL6 and melanoma: Elevated pre-treatment IL-6 levels have been associated with reduced ICI response rates by two independent studies on unresectable stage III or IV melanoma, including a study of 35 patients treated with nivolumab,25and a larger study of 140 patients treated with sequential administration of nivolumab followed by ipilimumab (or vice versa).17